-
1.发明公开BANDED CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS 审中-公开相关的纳米颗粒用量的活性控释制剂和方法
公开(公告)号：EP1933811A2
公开(公告)日：2008-06-25
申请号：EP06815377.4
申请日：2006-09-25
申请人： Alza Corporation
IPC分类号： A61K9/00
CPC分类号： A61K9/146 , A61K9/1075 , A61K9/145 , A61K9/1611 , A61K9/1652 , A61K9/2072 , A61K9/2077 , A61K9/2095 , B82Y5/00
摘要： Disclosed are controlled release dosage forms and related methods wherein controlled release of self-dispersing nanoparticle active agent formulations is provided by formulating porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation.
-
公开(公告)号：EP1083879B1
公开(公告)日：2004-09-29
申请号：EP99955212.8
申请日：1999-05-27
申请人： ALZA CORPORATION
发明人： AYER, Atul, D. , CHRISTOPHER, Carol, A. , GUINTA, Diane, R. , GUPTA, Suneel, K. , HAMEL, Lawrence, G. , HATAMKHANY, Zahedeh , LAM, Andrew, C. , SAKS, Samuel, R. , SHIVANAND, Padmaja , WEYERS, Richard, G. , WRIGHT, Jeri, D.
CPC分类号： A61K31/4402 , A61K9/0004 , A61K31/137 , A61K31/421 , A61K31/4422 , A61K31/4458 , G01N21/9508
摘要： Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
-
公开(公告)号：EP1083879A1
公开(公告)日：2001-03-21
申请号：EP99955212.8
申请日：1999-05-27
申请人： ALZA CORPORATION
发明人： AYER, Atul, D. , CHRISTOPHER, Carol, A. , GUINTA, Diane, R. , GUPTA, Suneel, K. , HAMEL, Lawrence, G. , HATAMKHANY, Zahedeh , LAM, Andrew, C. , SAKS, Samuel, R. , SHIVANAND, Padmaja , WEYERS, Richard, G. , WRIGHT, Jeri, D.
CPC分类号： A61K31/4402 , A61K9/0004 , A61K31/137 , A61K31/421 , A61K31/4422 , A61K31/4458 , G01N21/9508
摘要： Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
-
4.发明授权REDUCED FORMATE POLY(ALKYLENE OXIDES) WITH REBOXETINE FOR REDUCING IMPURITY FORMATION 有权聚（烯化氧）的简化格式瑞波西汀，以减少污染的形成
公开(公告)号：EP1503732B1
公开(公告)日：2008-10-08
申请号：EP03747606.6
申请日：2003-04-28
申请人： ALZA Corporation
IPC分类号： A61K9/00 , A61K47/34 , A61K31/765
CPC分类号： A61K31/5375 , A61K9/0004 , A61K9/2031 , A61K31/765 , A61K47/34
摘要： Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.
-
5.发明授权DOSAGE FORMS AND METHODS FOR PROVIDING EFFECTIVE REBOXETINE THERAPY WITH ONCE-A-DAY DOSING 有权剂型和以“一天一次”剂量的方法对于一个有效的REBOXETINTHERAPIE
公开(公告)号：EP1216031B1
公开(公告)日：2007-03-14
申请号：EP00963500.4
申请日：2000-09-15
申请人： ALZA CORPORATION
发明人： SEROFF, Sylvia , YAM, Noymi , AYER, Atul, D. , BHATT, Padmanabh , DESJARDIN, Michael, A. , LAM, Andrew, C. , EDGREN, David, E. , NIXON, Phillip, R.
IPC分类号： A61K9/22
CPC分类号： A61K31/5375 , A61K9/0004
摘要： Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.
-
公开(公告)号：EP1667653A1
公开(公告)日：2006-06-14
申请号：EP04788970.4
申请日：2004-09-23
申请人： ALZA CORPORATION
IPC分类号： A61K9/00 , A61K31/167
CPC分类号： A61K31/167 , A61K9/0004
摘要： The present invention is directed to a dosage form configured to provide the controlled release of an active agent formulation. A dosage form according to the present invention includes a reservoir containing an active agent formulation and an engine positioned at least partially within the reservoir. In order to reduce the possibility that the engine included in a dosage form of the present invention will separate from the reservoir either during or after fabrication of the dosage form of the present invention, the engine included in a dosage form according to the present invention is bonded to an inside surface of the reservoir. The present invention also includes methods for preparing a controlled release dosage form.
-
7.发明公开PERMEATION-RESISTANT OSMOTIC ENGINE AND DOSAGE FORM FOR CONTROLLED RELEASE OF A LIQUID ACTIVE AGENT FORMULATION 审中-公开PERMEATIONSFESTER渗透引擎和剂量液体活性配方控制下交付
公开(公告)号：EP1648409A2
公开(公告)日：2006-04-26
申请号：EP04779854.1
申请日：2004-07-30
申请人： ALZA CORPORATION
IPC分类号： A61K9/00
CPC分类号： A61K9/0004
摘要： The present invention relates to osmotic engines and dosage forms providing the controlled release of a liquid active agent formulation. More specifically, the present invention is directed to osmotic engines, dosage forms and methods that preserve osmotic engine functionality and reduce void volume formation is osmotically driven dosage form providing the controlled release of liquid active agent formulations.
-
8.发明公开REDUCED FORMATE POLY(ALKYLENE OXIDES) WITH SECONDARY AMINES FOR REDUCING IMPURITY FORMATION 有权聚（烯化氧）的简化格式瑞波西汀，以减少污染的形成
公开(公告)号：EP1503732A2
公开(公告)日：2005-02-09
申请号：EP03747606.6
申请日：2003-04-28
申请人： Alza Corporation
IPC分类号： A61K9/00 , A61K47/34 , A61K31/765
CPC分类号： A61K31/5375 , A61K9/0004 , A61K9/2031 , A61K31/765 , A61K47/34
摘要： Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.
-
9.发明公开DOSAGE FORMS AND METHODS FOR PROVIDING EFFECTIVE REBOXETINE THERAPY WITH ONCE-A-DAY DOSING 有权剂型和以“一天一次”剂量的方法对于一个有效的REBOXETINTHERAPIE
公开(公告)号：EP1216031A2
公开(公告)日：2002-06-26
申请号：EP00963500.4
申请日：2000-09-15
申请人： Alza Corporation
发明人： SEROFF, Sylvia , YAM, Noymi , AYER, Atul, D. , BHATT, Padmanabh , DESJARDIN, Michael, A. , LAM, Andrew, C. , EDGREN, David, E. , NIXON, Phillip, R.
IPC分类号： A61K9/22
CPC分类号： A61K31/5375 , A61K9/0004
摘要： Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
